Man uses spray
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Australia’s healthcare regulator TGA has enabled LTR Pharma (ASX:LTP) to dose the first patient with viagra nasal spray product SPONTAN.

Patients were prescribed through one select clinic managing a special access scheme on behalf of the TGA.

“The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma,” company chair Lee Rodne said.

“It demonstrates both the urgent need for fast-acting ED medication and SPONTAN’s potential to address a high unmet need for a fast and on-demand ED treatment.”

Rodne also noted the move allows the company to oversee real-world use of the product.

“We see SPONTAN as a valuable addition to our therapeutic capability,” Restorative Sexual Health Clinic founder Melissa Barrett said.

In the background, the company is gearing up to promote the drug and its backing science to international conferences and publications.

LTP last traded at 73cps.

LTP by the numbers
More From The Market Online
The Market Online Video

ASX Market Update: Unemployment remains steady at 4.1% | November 14, 2024

The ASX200 has been up 0.45% at 8,330 points in afternoon trade. Australia’s unemployment rate remained…
The Market Online Video

ASX Market Close: NAB predicts first rate cut will now be May |November 14, 2024

National Australia Bank (ASX:NAB) has become the first major bank to push out its prediction for…

Recce scores $6.75M R&D rebate

Recce Pharmaceuticals (ASX: RCE) has received a cash refund of $6,751,176 Research and Development (R&D) Tax…
HotCopper studio & website with Gumtree branding

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Let’s get straight to the point: of all the smallcaps in the Telecommunications index, The Market Ltd…